Premium
Rapid review: next generation of cord blood banks; transplantation and beyond
Author(s) -
Querol Sergio,
Samarkanova Dinara
Publication year - 2019
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.15466
Subject(s) - cord blood , stem cell , transplantation , immunology , medicine , blood product , umbilical cord , multipotent stem cell , red blood cell , immune system , leukemia , cancer research , biology , progenitor cell , surgery , microbiology and biotechnology
KEY IDEAS Cord blood (CB) is a medicinal product of human origin with unique cellular properties such as the presence of multipotent stem cells, naive immune cells, and fetal blood components. CB transplantation provides high rate of donor chimerism, and a good balance of graft‐versus‐host (GVH) and graft‐versus‐leukemia (GVL) effects. Use of CB for transplantation has decreased in recent years as haplo‐identical stem cell transplants have achieved similar short‐term clinical outcomes. For most patients, however, the optimal stem cell source remains unclear. CB inventories can be used as a starting material to develop new cellular medicines, and units with low cellular content can be converted to produce blood components like platelet‐rich plasma and red blood cell (RBC) units for special indications.